Decreased CBFβ dosage alters the percentage of monocytes/granulocytes and T cells in the spleen and thymus of 17.5-dpc fetuses
| Cell type/maker . | Genotype . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cbfb+/+ . | Cbfbrss/+ . | Cbfb+/− . | Cbfbrss/rss . | Cbfbrss/− . | ||||||
| Mean ± SD . | n . | Mean ± SD . | n . | Mean ± SD . | n . | Mean ± SD . | n . | Mean ± SD . | n . | |
| CD45+ splenocytes*† | 25.6 ± 2.4 | 21 | 24.0 ± 0.5 | 4 | 18.8 ± 2.7§ | 10 | 21.1 ± 3.9 | 4 | 16.3 ± 2.5‖ | 21 |
| CD45+ Gr-1+ Mac-1+ monocytes/granulocytes*‡ | 56.5 ± 2.7 | 4 | 61.0 ± 3.5 | 9 | ND | 29.4 ± 3.4‖ | 6 | 15.0 ± 2.5§ | 4 | |
| Ter119+ erythroid cells*† | 50.0 ± 4.5 | 10 | 52.3 ± 3.9 | 14 | ND | 39.0 ± 8.1 | 7 | 58.5 ± 8.9 | 5 | |
| CD19+ B cells*† | 3.0 ± 0.5 | 13 | 3.0 ± 0.4 | 3 | 3.0 ± 0.5 | 9 | 3.5 ± 0.5 | 3 | 3.6 ± 1.1 | 14 |
| Thymocytes | ||||||||||
| CD4+ CD8+ DP† | 49.0 ± 7.0 | 25 | 38.2 ± 4.0 | 9 | 36.5 ± 7.0 | 5 | 31.7 ± 9.0§ | 7 | 4.3 ± 3.3‖ | 25 |
| CD4+ CD8−† | 5.4 ± 0.4 | 40 | 6.4 ± 0.6 | 22 | 8.5 ± 1.7§ | 5 | 18.3 ± 2.2‖ | 7 | 7.3 ± 4.0 | 25 |
| CD4− CD8+† | 3.6 ± 0.7 | 25 | 4.7 ± 0.3 | 9 | 3.2 ± 1.3 | 5 | 2.1 ± 0.5 | 7 | 0.8 ± 0.4‖ | 25 |
| Spleen cellularity | 1.6 ± 0.2 × 106 | 7 | 1.5 ± 0.1 × 106 | 5 | 1.1 ± 0.1 × 106 | 8 | 5.3 ± 0.3 × 105§ | 3 | 4.8 ± 0.8 × 105§ | 6 |
| Thymus cellularity | 6.0 ± 0.5 × 106 | 12 | 4.0 ± 0.1 × 106 | 4 | 4.0 ± 0.5 × 106 | 6 | 8.3 ± 0.3 × 105‖ | 6 | 4.9 ± 1.2 × 105‖ | 14 |
| Cell type/maker . | Genotype . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cbfb+/+ . | Cbfbrss/+ . | Cbfb+/− . | Cbfbrss/rss . | Cbfbrss/− . | ||||||
| Mean ± SD . | n . | Mean ± SD . | n . | Mean ± SD . | n . | Mean ± SD . | n . | Mean ± SD . | n . | |
| CD45+ splenocytes*† | 25.6 ± 2.4 | 21 | 24.0 ± 0.5 | 4 | 18.8 ± 2.7§ | 10 | 21.1 ± 3.9 | 4 | 16.3 ± 2.5‖ | 21 |
| CD45+ Gr-1+ Mac-1+ monocytes/granulocytes*‡ | 56.5 ± 2.7 | 4 | 61.0 ± 3.5 | 9 | ND | 29.4 ± 3.4‖ | 6 | 15.0 ± 2.5§ | 4 | |
| Ter119+ erythroid cells*† | 50.0 ± 4.5 | 10 | 52.3 ± 3.9 | 14 | ND | 39.0 ± 8.1 | 7 | 58.5 ± 8.9 | 5 | |
| CD19+ B cells*† | 3.0 ± 0.5 | 13 | 3.0 ± 0.4 | 3 | 3.0 ± 0.5 | 9 | 3.5 ± 0.5 | 3 | 3.6 ± 1.1 | 14 |
| Thymocytes | ||||||||||
| CD4+ CD8+ DP† | 49.0 ± 7.0 | 25 | 38.2 ± 4.0 | 9 | 36.5 ± 7.0 | 5 | 31.7 ± 9.0§ | 7 | 4.3 ± 3.3‖ | 25 |
| CD4+ CD8−† | 5.4 ± 0.4 | 40 | 6.4 ± 0.6 | 22 | 8.5 ± 1.7§ | 5 | 18.3 ± 2.2‖ | 7 | 7.3 ± 4.0 | 25 |
| CD4− CD8+† | 3.6 ± 0.7 | 25 | 4.7 ± 0.3 | 9 | 3.2 ± 1.3 | 5 | 2.1 ± 0.5 | 7 | 0.8 ± 0.4‖ | 25 |
| Spleen cellularity | 1.6 ± 0.2 × 106 | 7 | 1.5 ± 0.1 × 106 | 5 | 1.1 ± 0.1 × 106 | 8 | 5.3 ± 0.3 × 105§ | 3 | 4.8 ± 0.8 × 105§ | 6 |
| Thymus cellularity | 6.0 ± 0.5 × 106 | 12 | 4.0 ± 0.1 × 106 | 4 | 4.0 ± 0.5 × 106 | 6 | 8.3 ± 0.3 × 105‖ | 6 | 4.9 ± 1.2 × 105‖ | 14 |
ND indicates not done.
Spleen.
Expressed as percentage of all spleen or thymus cells expressing the antigen.
Cells gated for CD45 expression were analyzed for Gr-1 and Mac-1 expression. Values represent the percentage of CD45+ cells that were also Gr-1+Mac-1+.
Significantly different from Cbfb+/+ at P < .001 by unpaired 2-tailed Student t test.
Significantly different from Cbfb+/+ at P < .001.